Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) shares jumped 26% after the biotech reported encouraging early results from its phase I trial of HG-CT-1, an experimental CAR-T therapy for relapsed or refractory acute myeloid leukaemia (AML).
The London-listed company said its third patient had been treated successfully, with the therapy meeting initial safety targets and showing signs of efficacy.
Standard tests detected no remaining AML cells following treatment. The patient continues to be monitored under the US Food and Drug Administration–approved protocol.
Data from the first three patients at the lowest dose will now be reviewed by an independent safety board, which will decide whether the study can move to a higher dose.
The trial is structured to assess safety and tolerability first, but also includes key secondary measures such as overall and progression-free survival, duration of response, and AML-specific outcomes.
Vladislav Sandler, Hemogenyx’s chief executive, called the development “an important milestone” for patients with few treatment options. “We are encouraged by the favourable safety profile observed to date, together with the early signals of efficacy,” he said.
The company said further updates will follow as the trial progresses and longer-term outcomes are assessed.
The shares rose 315p to 1,548p.